47592 Federal Register / Vol. 74, No. 178 / Wednesday, September 16, 2009 / Notices 

Contact Person: Denise Wiesch, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3150, 

MSC 7770, Bethesda, MD 20892, (301) 435– 

0684, wieschd@csr.nih.gov. 

Name of Committee: Risk, Prevention and 

Health Behavior Integrated Review Group; 

Behavioral Medicine, Interventions and 

Outcomes Study Section. 

Date: October 5–6, 2009. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard by Marriott, 1000 

Aliceanna Street, Baltimore, MD 21202. 

Contact Person: Lee S. Mann, JD, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3186, 

MSC 7848, Bethesda, MD 20892, 301–435– 

0677, mannl@csr.nih.gov. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group; 

Arthritis, Connective Tissue and Skin Study 

Section. 

Date: October 5–6, 2009. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Aftab A. Ansari, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4108, 

MSC 7814, Bethesda, MD 20892, (301) 594– 

6376, ansaria@csr.nih.gov. 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Adult Psychopathology and Disorders 

of Aging Study Section. 

Date: October 5–6, 2009. 

Time: 8:30 a.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: InterContinental Harbor Court 

Baltimore, 550 Light Street, Baltimore, MD 

21202. 

Contact Person: Estina E. Thompson, PhD, 

MPH, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3178, 

MSC 7848, Bethesda, MD 20892, 301–496– 

5749, thompsone@mail.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Clinical Neuroscience and 

Neurodegeneration Study Section. 

Date: October 5–6, 2009. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Avenue, NW., Washington, DC 20037. 

Contact Person: Seetha Bhagavan, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5194, 

MSC 7846, Bethesda, MD 20892, (301) 435– 

1121, bhagavas@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; SAT and 

BTSS Member Conflict. 

Date: October 5, 2009. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Telephone Conference Call) 

Contact Person: Roberto J. Matus, MD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5108, 

MSC 7854, Bethesda, MD 20892, (301) 435– 

2204, matusr@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 9, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–22218 Filed 9–15–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel. SBIR. 

Date: October 13, 2009. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health/ 

NCCAM, 6707 Democracy Blvd, Suite 401, 

Bethesda, MD 20892. (Telephone Conference 

Call) 

Contact Person: Ray Bramhall, PhD, 

Scientific Review Officer, National Center for 

Complementary and Alternative Medicine, 

6707 Democracy Blvd., Suite 401, Bethesda, 

MD 20892. bramhallr@mail.nih.gov. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel. Basic and 

Preclinical Research and Career Development 

Applications. 

Date: October 19–20, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard by Marriott, Gaithersburg 

Washingtonian Center, 204 Boardwalk Place, 

Gaithersburg, MD 20878. 

Contact Person: Peter Kozel, PhD, 

Scientific Review Officer, NCCAM,6707 

Democracy Boulevard, Suite 401, Bethesda, 

MD 20892–5475. 301–496–8004. 

kozelp@mail.nih.gov. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel. Fellowship and 

Training Applications. 

Date: October 28, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Legacy Hotel and Meeting 

Center, 1775 Rockville Pike, Rockville, MD 

20852. 

Contact Person: Peter Kozel, PhD, 

Scientific Review Officer, NCCAM, 6707 

Democracy Boulevard, Suite 401, Bethesda, 

MD 20892–5475. 301–496–8004. 

kozelp@mail.nih.gov. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel. Clinical Science. 

Date: October 29–30, 2009. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Laurie Friedman Donze, 

PhD, Scientific Review Officer, Office of 

Scientific Review, National Center for 

Complementary and Alternative Medicine, 

NIH, 6707 Democracy Blvd., Suite 401, 

Bethesda, MD 20892. 301–402–1030. 

donzel@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.213, Research and Training 

in Complementary and Alternative Medicine, 

National Institutes of Health, HHS) 

Dated: September 10, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–22311 Filed 9–15–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2001–F–0049] (formerly 

Docket No. 2001F–0047) 

National Fisheries Institute; Filing of 

Food Additive Petition; Amendment 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is amending the 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 74, No. 178 / Wednesday, September 16, 2009 / Notices 47593 

filing notice for a food additive petition 

filed by the National Fisheries Institute, 

to provide for the safe use of ionizing 

radiation for control of foodborne 

pathogens in crustaceans and processed 

crustaceans. 

FOR FURTHER INFORMATION CONTACT: 

Lane A. Highbarger, Center for Food 

Safety and Applied Nutrition (HFS– 

255), Food and Drug Administration, 

5100 Paint Branch Pkwy., College Park, 

MD 20740, 301–436–1204. 

SUPPLEMENTARY INFORMATION: Under the 

Federal Food, Drug, and Cosmetic Act 

(sec. 409(b)(5) (21 U.S.C. 348(b)(5))), a 

notice was published in the Federal 

Register of February 6, 2001 (66 FR 

9086) announcing that a food additive 

petition (FAP 1M4727) had been filed 

by the National Fisheries Institute, 7918 

Jones Branch Dr., McLean, VA 22102, 

proposing that the food additive 

regulations in part 179 Irradiation in the 

Production, Processing and Handling of 

Food (21 CFR part 179) be amended to 

provide for the safe use of ionizing 

radiation for control of foodborne 

pathogens in raw-, frozen-, cooked-, 

partially cooked-, shelled-, or dried 

crustaceans, or cooked- or ready-to-cook 

crustaceans processed with batter, 

breading, spices, or small amounts of 

other food ingredients. 

Subsequent to the publication of the 

filing notice, the National Fisheries 

Institute amended the scope of their 

petition so as to exclude the use of 

breading or batter. FDA received a letter 

from the National Fisheries Institute, 

dated July 16, 2009, asking FDA to 

modify the scope of the petition so that 

breading and batter are not included. 

Therefore, FDA is amending the filing 

notice of February 6, 2001, to state that 

the National Fisheries Institute is 

proposing that the food additive 

regulations in part 179 be amended to 

provide for the use of ionizing radiation 

for the control of foodborne pathogens 

in raw-, frozen-, cooked-, partially 

cooked-, shelled-, or dried-crustaceans 

or cooked- or ready-to-cook crustaceans 

processed with spices or small amounts 

of other food ingredients. 

The agency has determined under 21 

CFR 25.32(i) that this action is of a type 

that does not individually or 

cumulatively have a significant effect on 

the human environment. Therefore, 

neither an environmental assessment 

nor an environmental impact statement 

is required. 

Dated: September 4, 2009. 

Laura M. Tarantino, 

Director, Office of Food Safety, Center for 

Food Safety and Applied Nutrition. 

[FR Doc. E9–22008 Filed 9–15–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number NIOSH–057] 

Request for Information on 1- 

Bromopropane 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of public comment 

period. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) intends to 

evaluate the scientific data on the 

brominated organic solvent, 1- 

Bromopropane (1–BP, CAS # 106–94–5, 

also known as n-propyl bromide), and 

develop appropriate communication 

documents, such as a Current 

Intelligence Bulletin, Criteria Document 

and/or other informational products, 

and establish a Recommended Exposure 

Limit (REL) for 1–BP. NIOSH is 

requesting information on the following: 

(1) published and unpublished reports 

and findings from in vitro and in vivo 

toxicity studies with 1–BP, (2) 

information on possible health effects 

observed in workers exposed to 1–BP, 

(3) information on workplaces and 

products in which 1–BP can be found, 

(4) description of work tasks and 

scenarios with a potential for exposure 

to 1–BP, (5) workplace exposure data, 

and (6) information on control measures 

(e.g., engineering controls, work 

practices, personal protective 

equipment) that are being used in 

workplaces where potential exposures 

to 1–BP occur. 

Public Comment Period: Comments 

must be received by December 14, 2009. 

ADDRESSES: You may submit comments, 

identified by docket number NIOSH– 

057, by any of the following methods: 

• Mail: NIOSH Docket Office, Robert 

A. Taft Laboratories, MS–C34, 4676 

Columbia Parkway, Cincinnati, OH 

45226. 

• Facsimile: (513) 533–8285. 

• E-mail: nioshdocket@cdc.gov. 

All information received in response 

to this notice will be available for public 

examination and copying at the NIOSH 

Docket Office, 4676 Columbia Parkway, 

Cincinnati, Ohio 45226. A complete 

electronic docket containing all 

comments submitted will be available 

on the NIOSH Web page at http:// 

www.cdc.gov/niosh/docket, and 

comments will be available in writing 

by request. NIOSH includes all 

comments received without change in 

the docket, including any personal 

information provided. 

FOR FURTHER INFORMATION CONTACT: G. 

Scott Dotson, PhD, NIOSH, Robert A 

Taft Laboratories, MS–C32, 4676 

Columbia Parkway, Cincinnati, OH 

45226, telephone (513) 533–8540. 

SUPPLEMENTARY INFORMATION: 1–BP is a 

brominated organic solvent that has 

received increased global attention in 

recent years as a potential alternative for 

ozone depleting substances and other 

compounds with known adverse health 

effects, such as chlorofluorocarbons 

(CFC), hydrochlorofluorocarbons 

(HCFC), and methylene chloroform. 1– 

BP is used in multiple industrial 

processes including vapor and 

immersion degreasing operations, and 

as a solvent in industries using aerosolapplied adhesives; 1–BP is also 

proposed as a replacement solvent for 

perchloroethylene in the dry-cleaning 

sector. The National Toxicology 

Program (NTP) estimated that 

approximately 8.2 million pounds (lbs) 

of 1–BP were used in the United States 

(U.S.) in 2002. Estimates of the number 

of workers exposed to 1–BP are 

unavailable due to limited exposure 

data and its relatively recent 

introduction into domestic commerce. 

The toxic nature of 1–BP is not fully 

understood. Recently published case 

reports describe possible adverse health 

effects, including neurotoxicity, 

following occupational exposures to 1– 

BP. The findings of animal toxicity 

studies in rats and mice indicate that 1– 

BP may be a reproductive and 

developmental toxicant, in addition a 

neurotoxicant. No occupational 

exposure limits for 1–BP have been 

established by NIOSH or the 

Occupational Safety and Health 

Administration (OSHA). 

NIOSH seeks to obtain materials, 

including published and unpublished 

reports and research findings, to 

evaluate the possible health risks of 

occupational exposure to 1–BP. 

Examples of requested information 

include, but are not limited to, the 

following: 

(1) Identification of industries or 

occupations in which exposures to 1–BP 

may occur. 

(2) Trends in the production and use 

of 1–BP and 1–BP containing 

compounds. 

(3) Description of work tasks and 

scenarios with a potential for exposure 

to 1–BP. 


srobinson on DSKHWCL6B1PROD with NOTICES